Summary of Key Points from the Conference Call Company Overview - The company discussed is 科笛 (Kedi), focusing on the commercialization of external Finasteride and Minocycline products, with significant revenue targets set for 2025 [2][5]. Industry and Product Insights - **External Finasteride**: - Revenue target for 2025 is over 50 million RMB, with expectations to achieve at least 200 million RMB within 12 months post-commercialization [2][5]. - Priced at 998 RMB, positioned in the high-end market, with potential for price adjustments [2][7]. - Monthly usage cost is comparable to competitors, but with better efficacy and fewer side effects [2][7]. - **Minocycline**: - Initial pricing set at 1,880 RMB, targeting the medical aesthetics channel, aiming to fill a gap in safe and effective topical antibiotics [2][10]. - Expected to exceed 20 million RMB in sales for 2025, with a target of at least 100 million RMB in the first year post-commercialization [4][5]. Commercialization Progress - Both products have shown strong initial sales performance, with external Finasteride completing import processes and shipping nationwide [3][4]. - Online pre-sales for Minocycline on platforms like JD.com have exceeded expectations, indicating robust market acceptance [3][4]. Financial Performance and Strategy - The company faced revenue impacts due to the cessation of collaboration with the OMA brand, but GSV showed actual growth when excluding this impact [4][13]. - The commercial team consists of approximately 120-130 members, with a focus on optimizing brand operations and sales efficiency [4][18]. Competitive Landscape - The external Finasteride market has competitors, such as Chengdu Beite, which may launch products in the near future [12][24]. - The company is aware of the competitive dynamics and is prepared to adjust its R&D and registration strategies accordingly [12][24]. Research and Development - The company is advancing a new drug project, 龙井村溶脂针, expected to enter Phase III clinical trials soon, which could enhance overall product synergy [2][15]. - Plans to potentially shift core ingredient production domestically to mitigate international supply chain risks [11]. Future Outlook - The company anticipates reaching a sales volume of 1 billion RMB for both key products by 2026, with stable gross margins projected between 70% and 80% [22][24]. - The strategy includes expanding online sales channels and integrating related cosmetic products to enhance brand value [20][21]. Conclusion - The company is positioned for growth with a strong product pipeline, effective commercialization strategies, and a focus on maintaining competitive advantages in the market [2][4][15].